Drug diffusion along an intact mammalian cochlea by Sadreev, II et al.
This is a repository copy of Drug diffusion along an intact mammalian cochlea.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/144889/
Version: Accepted Version
Article:
Sadreev, II, Burwood, GW, Flaherty, SM et al. (4 more authors) (2019) Drug diffusion along
an intact mammalian cochlea. Frontiers in Cellular Neuroscience. ISSN 1662-5102 
https://doi.org/10.3389/fncel.2019.00161
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless 
indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by 
national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of 
the full text version. This is indicated by the licence information on the White Rose Research Online record 
for the item. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
  
 
Drug diffusion along an intact
mammalian cochlea
 
Ildar I.  Sadreev1*,  George W.  Burwood2,  Samuel M.  Flaherty3,  Jongrae Kim4,  Ian J.  Russell3,
Timur I.  Abdullin5,  Andrei N.  Lukashkin3*
 
1Imperial College London, United Kingdom, 2Oregon Healt h & Science Universit y,  Unit ed States,
3Universi t y of  Bright on,  Unit ed Kingdom,  4Universit y of  Leeds,  Unit ed Kingdom,  5Kazan Federal
Universi t y,  Russia
 Submit t ed t o Journal:
 
Front iers in Cel lular Neuroscience
 Specialt y Sect ion:
 
Cel lular Neuroscience Archive
 Art icle type:
 
Original  Research Art icle
 Manuscript  ID:
 
450802
 Received on:
 
28 Jan 2019
 Revised on:
 
27 Mar 2019
 Front iers websit e link:
 www. f ront iersin. org
In revi
ew
  
 
Conflict  of interest  statement
 The authors declare that  the research was conducted in the absence of any commercial or financial
relat ionships that  could be construed as a potential conflict  of interest
  
 
Author contribut ion statement
 
ANL,  IJR and TIA conceived and designed t he st udy.  GWSB, SMF and ANL performed t he experiment s and analysed experimental
result s.  IIS,  JK and ANL developed t he model.  IIS performed numerical simulat ions and f it t ing t o t he experimental data.  Al l  authors
cont ribut ed t o analysis and discussion of  t he resul t s.  IIS and ANL wrot e t he manuscript  wit h cont ribut ion f rom al l  aut hors.
  
 
Keywords
 
Cochlea,  Drug del ivery,  sal icylate,  cochlear amplif ier,  cochlear round window
  
 
Abstract
Word count : 340
 
Int rat ympanic drug administ rat ion depends on t he abi l i t y of  drugs t o pass t hrough t he round window membrane (RW) at  t he base
of  t he cochlea and dif fuse f rom t his locat ion t o t he apex.  While t he RW permeabil i t y for many dif ferent  drugs can be promot ed,
passive di f fusion along t he narrowing spiral  of  t he cochlea is l imit ed.  Earl ier measurement s of  t he dist r ibut ion of  marker ions,
cort icost eroids and ant ibiot ics demonst rat ed t hat  t he concent rat ion of  subst ances appl ied t o t he RW was t wo t o t hree orders of
magnit ude higher in t he base compared t o t he apex.  The measurement s,  however,  involved perforat ing t he cochlear bony wal l
and,  in some cases,  sampling peri lymph.  These manipulat ions can change t he f low rat e of  peri lymph and lead t o int ake of  peri lymph
t hrough t he cochlear aqueduct ,  t hereby disguising concent rat ion gradient s of  t he del ivered subst ances.  In t his st udy,  t he
suppressive ef fect  of  sal icylat e on cochlear amplif icat ion via block of  t he outer hair cel l  (OHC) somat ic mot i l i t y was ut i l ized t o
assess sal icylate dif fusion along an intact  guinea pig cochlea in vivo.  Sal icylate solut ion was appl ied t o t he RW and t hreshold
elevat ion of  audit ory nerve responses was measured at  di f ferent  t imes and f requencies af t er appl icat ion.  Resul t ant  concent rat ions
of  sal icylat e along t he cochlea were calculated by f it t ing t he experimental data using a mathemat ical model of  t he dif fusion and
clearing of  sal icylat e in a t ube of  variable diamet er combined wit h a model describing sal icylat e act ion on cochlear amplif icat ion.
Concent rat ions reach a st eady-st at e at  dif ferent  t imes for dif ferent  cochlear locat ions and i t  t akes longer t o reach t he
st eady-st at e at  more apical  locat ions.  Even at  t he st eady st at e,  t he predict ed concent rat ion at  t he apex negl igible.  Model
predict ions for t he geomet ry of  t he longer human cochlea show even higher dif ferences in t he st eady-st at e concent rat ions of  t he
drugs bet ween cochlear base and apex.  Our f indings conf irm conclusions t hat  achieving t herapeut ic drug concent rat ions
t hroughout  t he ent ire cochlear duct  is hardly possible when t he drugs are appl ied t o t he RW and are dist r ibut ed via passive
dif fusion.  Assist ed met hods of  drug del ivery are needed t o reach a more uniform dist ribut ion of  drugs along t he cochlea.
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ABSTRACT 15 
Intratympanic drug administration depends on the ability of drugs to pass through the round 16 
window membrane (RW) at the base of the cochlea and diffuse from this location to the apex. 17 
While the RW permeability for many different drugs can be promoted, passive diffusion along 18 
the narrowing spiral of the cochlea is limited. Earlier measurements of the distribution of 19 
marker ions, corticosteroids and antibiotics demonstrated that the concentration of substances 20 
applied to the RW was two to three orders of magnitude higher in the base compared to the 21 
apex. The measurements, however, involved perforating the cochlear bony wall and, in some 22 
cases, sampling perilymph. These manipulations can change the flow rate of perilymph and 23 
lead to intake of perilymph through the cochlear aqueduct, thereby disguising concentration 24 
gradients of the delivered substances. In this study, the suppressive effect of salicylate on 25 
cochlear amplification via block of the outer hair cell (OHC) somatic motility was utilized to 26 
assess salicylate diffusion along an intact guinea pig cochlea in vivo. Salicylate solution was 27 
applied to the RW and threshold elevation of auditory nerve responses was measured at 28 
different times and frequencies after application. Resultant concentrations of salicylate along 29 
the cochlea were calculated by fitting the experimental data using a mathematical model of the 30 
diffusion and clearing of salicylate in a tube of variable diameter combined with a model 31 
describing salicylate action on cochlear amplification. Concentrations reach a steady-state at 32 
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different times for different cochlear locations and it takes longer to reach the steady-state at 33 
more apical locations. Even at the steady state, the predicted concentration at the apex is 34 
negligible. Model predictions for the geometry of the longer human cochlea show even higher 35 
differences in the steady-state concentrations of the drugs between cochlear base and apex. Our 36 
findings confirm conclusions that achieving therapeutic drug concentrations throughout the 37 
entire cochlear duct is hardly possible when the drugs are applied to the RW and are distributed 38 
via passive diffusion. Assisted methods of drug delivery are needed to reach a more uniform 39 
distribution of drugs along the cochlea. 40 
INTRODUCTION 41 
The mammalian cochlea is one of the least accessible organs for drug delivery (Salt and 42 
Plontke, 2009; Rivera et al., 2012; El Kechai et al., 2015; Hao and Li, 2019). Systemic 43 
administration of many drugs, notably the most frequently used corticosteroids and 44 
aminoglycoside antibiotics, is severely limited by the blood-labyrinth barrier (Salt and Hirose, 45 
2018). Local intratympanic administration (Schuknecht, 1956; Bowe and Jacob, 2010) would 46 
be a preferable option for these drugs and local delivery is the only option for many old and 47 
newly emerging classes of drugs and therapies including local anaesthetics, antioxidants, 48 
apoptosis inhibitors, neurotransmitters and their antagonists, monoclonal antibodies, growth 49 
factors, signalling pathway regulators and genetic material (see Devare et al., 2018; Hao and 50 
Li, 2019 for the latest reviews). Intratympanic administration of drugs relies on their remaining 51 
in contact with the round window membrane (RW) (a membranous opening in the bony wall 52 
of the cochlear into the middle ear) long enough to allow their diffusion into the perilymph of 53 
the scala tympani (ST). The ability of drugs to pass through the RW does not, however, 54 
guarantee their sufficient distribution along the cochlear spiral. Drug distribution in the ST is 55 
limited by the low flow rate of perilymph within the cochlea and by cochlear geometry. The 56 
longitudinal flow of perilymph in the cochlea has been shown to be relatively slow, if present 57 
at all, (Ohyama et al., 1988) and drug distribution in the perilymph is dominated by passive 58 
diffusion. Passive diffusion along the ST is, however, constrained because the cochlea is a 59 
relatively long and narrow tube with a cochlear cross-section that decreases gradually from the 60 
RW at the base to the apex. It is in the cochlear apex where human speech processing is initiated 61 
(e.g. Nuttall et al., 2018) and where drug delivery to the cochlea has greatest potential 62 
therapeutic and socioeconomic impact. 63 
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However, direct measurements of the distribution of marker ions and contrasting agents (Salt 64 
and Ma, 2001; Haghpanahi et al., 2013), corticosteroids (Plontke et al., 2008; Creber et al., 65 
2018) and antibiotics (Mynatt et al., 2006; Plontke et al., 2007a) or measurements of the 66 
physiological effects of drugs (Chen et al., 2005; Borkholder et al., 2010) demonstrated that 67 
the concentration of substances applied to the RW was much higher in the cochlear base than 68 
in the apex. These measurements, however, involved perforating the cochlear bony wall and, 69 
in some cases, sampling perilymph. These manipulations can change the flow rate of perilymph 70 
(Ohyama et al., 1988; Salt and Ma, 2001) and lead to the intake of cerebrospinal fluid through 71 
the cochlear aqueduct (Salt et al., 2003), thereby disguising concentration gradients of the 72 
delivered substances. 73 
A few studies investigated the distribution of substances applied to the RW in the intact cochlea 74 
without breaking cochlear boundaries. This was done mainly in morphological studies 75 
investigating the distribution of dexamethasone and other substances along the cochlea after 76 
their intratympanic administration (Saijo and Kimura, 1984; Imamura and Adams, 2003; 77 
Hargunani et al., 2006; Grewal et al., 2013). While these studies confirmed the existence of 78 
base-to-apex gradients, the actual concentrations of substances along the cochlea were not 79 
measured. Borkholder et al. (2014) measured the threshold elevation of distortion product 80 
otoacoustic emission (DPOAE) produced by primary tones of different frequencies after 81 
intratympanic application of salicylate. Salicylate affects cochlear amplification in a 82 
concentration-dependent manner but the DPOAE is a nonlinear phenomenon and the 83 
dependence of DPOAE thresholds on the primary tone level and cochlear amplification is 84 
complex (Lukashkin et al., 2002). As a result, salicylate concentrations along the cochlear 85 
spiral cannot be easily derived from the DPOAE threshold elevations. 86 
The purpose of the current study is to quantify drug diffusion from the RW along an intact 87 
guinea pig cochlea, to identify the factors that limit passive drug diffusion along the cochlea, 88 
and to analyse possible solutions to overcome these limitations. Salicylate was used as a model 89 
drug with well-characterized physiological effects. A mathematical model, which includes a 90 
diffusion component and a biophysical component describing the action of salicylate on the 91 
cochlear amplifier was validated using experimental data and used to assess the distribution of 92 
substances along the human cochlea. 93 
MATERIALS AND METHODS 94 
Animals 95 
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Pigmented guinea pigs of similar weight (350-360 g) were anaesthetised with the neurolept 96 
anaesthetic technique (0.06 mg/kg body weight atropine sulphate s.c., 30 mg/kg pentobarbitone 97 
i.p., 500 Pl/kg Hypnorm i.m.). Additional injections of Hypnorm were given every 40 minutes. 98 
Additional doses of pentobarbitone were administered as needed to maintain a non-reflexive 99 
state. The heart rate was monitored with a pair of skin electrodes placed on both sides of the 100 
thorax. The animals were tracheotomized and artificially respired, and their core temperature 101 
was maintained at 38qC with a heating blanket and a heated head holder. All procedures 102 
involving animals were performed in accordance with UK Home Office regulations with 103 
approval from the local ethics committee. 104 
Signal Generation and Recording 105 
The middle ear cavity of the ear used for the measurements was opened to reveal the RW. 106 
Compound action potentials (CAPs) of the auditory nerve were measured from the cochlear 107 
bony ridge in the proximity of the RW membrane using Teflon-coated silver wire coupled to 108 
laboratory designed and built extracellular amplifier (James Hartley). Thresholds of the N1 109 
peak of the CAP were estimated visually using 10 ms tone stimuli at a repetition rate of 10 Hz. 110 
For acoustic stimulation sound was delivered to the tympanic membrane by a closed acoustic 111 
V\VWHPFRPSULVLQJWZR%UXHODQG.MDHUò´PLFURSKRQHVIRUGHOLYHULQJWRQHVDQGDVLQJOH112 
%UXHODQG.MDHUò´PLFURSKRQe for monitoring sound pressure at the tympanum. The 113 
microphones were coupled to the ear canal via 1 cm long, 4 mm diameter tubes to a conical 114 
speculum, the 1 mm diameter opening of which was placed about 1 mm from the tympanum. 115 
The closed sound system was calibrated in situ for frequencies between 1 and 50 kHz. Known 116 
sound pressure levels were expressed in dB SPL re 2u10-5 Pa.  117 
All acoustic stimuli in this work were shaped with raised cosines of 0.5 ms duration at the 118 
beginning and at the end of stimulation. White noise for acoustical calibration and tone 119 
sequences for auditory stimulation were synthesised by a Data Translation 3010 board at 250 120 
kHz and delivered to the microphones through low-pass filters (100 kHz cut-off frequency). 121 
Signals from the acoustic measuring amplifier (James Hartley) were digitised at 250 kHz using 122 
the same board and averaged in the time domain. Experimental control, data acquisition and 123 
data analysis were performed using a PC with programmes written in MATLAB (The 124 
MathWorks. Inc. 2018a). 125 
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5 Pl of sodium salicylate solution (either 100 mM in experiments on salicylate diffusion in the 126 
ST RU0LQH[SHULPHQWVZLWKFRPSOHWHEORFNRIWKHFRFKOHDUDPSOLILHULQ+DQNV¶%DODQFHG127 
Salt Solution were placed on the RW using pipettes. The solution was removed from the RW 128 
using paper wicks to observe the wash out effect. 129 
Model Overview 130 
Diffusion and Clearing Equation 131 
For the purpose of modelling, the ST is approximated by a tube with a decreasing diameter 132 
similar to that described in previous models, for example by Plontke et al. (2007b) (Figure 133 
1A). The radii of the tube, (0)r  and ( )r l , are equal to a   and b  at 0x  and ,x l  respectively, 134 
where l  is the ST length. All the dimensions are known (Thorne et al., 1999) and symmetry 135 
along y  and z axes is assumed. Zero longitudinal perilymph flow in the compartment is 136 
assumed (Ohyama et al., 1988) and only the passive diffusion of a drug (salicylate) with 137 
diffusion coefficient dk  is considered. In addition to diffusion, there is also clearing of the drug 138 
characterized by the clearing coefficient ck . This clearing can be represented simply as a leak 139 
through the scala boundary (e.g. loss to the vasculature and tissues, and to other cochlear 140 
compartments). The diffusion and clearing processes are assumed to be completely 141 
independent. Because the tube radius is much smaller than its length, i.e. ( )r x l  for all x  in 142 
[0, ]l , only diffusion along x  axis is considered and the concentration ( , )c x t  within each cross-143 
section for a fixed instance t  is assumed to be constant, i.e. it does not change along the y  axis. 144 
If the area of the cross-section is ( )S x  then the diffusion can be described by the following 145 
partial differential equation (see Appendix for detailed derivation): 146 
2( , ) 1 ( , )( ) ( , ) ,( ) ( )
c
d
kdc x t d dc x tS x k c x t
dt S x dx dx r x
§ ·     ¨ ¸© ¹  (1) 147 
with the boundary conditions 148 
(0, ) ,rwc t c   (2) 149 
( , ) 0d
dc l tk
dx
   (3) 150 
and initial conditions 151 
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(0,0) ; 0,rwc c x   (4) 152 
( ,0) 0; 0.c x x !   (5) 153 
The diffusion coefficient dk  is known (Lide, 2002) but the clearing coefficient ck  is unknown. 154 
The ratio of the diffusion and clearing coefficients can, however, be found via fitting the 155 
experimental data. The physical meaning of /d ck k  can be described as the ratio between the 156 
amount of substance that diffuses through a unit surface normal to the direction of diffusion 157 
for a unit concentration gradient and the amount of drug that is cleared through a unit surface 158 
normal to the direction of substance exit for a unit substance concentration, both for unit time 159 
duration. The diffusion/clearing equation was validated using experimental data on the 160 
physiological effect of salicylate on the CAP thresholds. Because the salicylate concentrations 161 
could not be directly inferred from the physiological effect of salicylate, a biophysical element 162 
of the model was developed allowing calculations of the salicylate concentrations along the 163 
cochlea.  164 
 165 
Link between position and frequency 166 
 
FIGURE 1. Schematic presentation of (A) the scala tympani (ST) approximated by a 
tube of decreasing diameter and (B) the cochlear amplifier modelled as a system with 
positive feedback provided by the outer hair cells (OHCs). 
In revi
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The dependence between frequency of stimulation f  and frequency position along the length 167 
x of the basilar membrane for the guinea pig cochlea is defined by the Greenwood equation 168 
(Greenwood, 1990) 169 
 ( ) 10 xf x A D E   , (6) 170 
where 0.35A , 2.1/18.5D  , 0.85E   and x l x   meaning that the starting point for x  171 
in Greenwood (1990) is at the apex and not the base of the cochlea, as in this study. 172 
Cochlear amplifier 173 
The cochlear amplifier is represented by a positive feedback system (Figure 1B) with feedback 174 
gain ( , ( ))H x c t  due to force generation by the OHCs (Mountain et al., 1983; Yates, 1990; 175 
Lukashkin and Russell, 1999). The following assumptions are made for a small signal, linear 176 
regime: 177 
1. The CAP threshold is observed for different sound pressure ( , ( ))inP x c t  at the 178 
tympanum but for the same BM displacements, i.e. for the same constant pressure 179 
( )outP x
 at the BM for any given frequency/place x  during manipulations with the 180 
cochlear amplifier. The assumption is based on good correspondence between neural 181 
and BM thresholds at the CF (Ruggero et al., 2000; Temchin et al., 2008). 182 
2. Feedback gain ( , ( ))H x c t  is proportional to the OHC force ( , ( ))F x c t  for any given 183 
frequency/place in the cochlea 184 
( , ( )) ( , ( )),H x c t F x c tD   (7) 185 
where D  is the gain constant. The initial feedback gain ( ,0)H x  for any frequency/place 186 
before application of salicylate can be found empirically (see below). 187 
3. Salicylate changes only feedback gain ( , ( ))H x c t  through changes in ( , ( ))F x c t . 188 
4. In line with other modelling studies (e.g. Meaud and Grosh, 2014; Ni et al., 2016) it is 189 
assumed that pressure/displacement at the BM is a linear combination of the passive 190 
BM response due to acoustic stimulation and active response due to the OHC forces. 191 
The link between local salicylate concentration ( , )c x t  and reduction in force ( , ( ))FR x c t  192 
generated by the OHCs can be described by the Hill function (Hallworth, 1997) 193 
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max
( , )( , ( )) ( , )
n
n n
c x tFR x c t V
k c x t
   , (8) 194 
where 
max 71.629V  , 0.101k   and 0.983n  . 195 
The reduction in force is linked to the force before ( ,0)F x  and after ( , ( ))F x c t  salicylate 196 
application as 197 
( ,0) ( , ( )) ( , ( ))( , ( )) 1( ,0) ( ,0)
F x F x c t F x c tFR x c t
F x F x
    (9) 198 
or, 199 
 ( , ( )) ( ,0) 1 ( , ( )) .F x c t F x FR x c t     (10) 200 
It can be written for any given frequency/place before salicylate application at 0t   (Figure 201 
1B) 202 
( )
,( ,0) 1 ( ,0)
out
in
P x G
P x G H x
    (11) 203 
where G  is the open loop gain. Similarly, at time t  after salicylate application 204 
( )
.( , ( )) 1 ( , ( ))
out
in
P x G
P x c t G H x c t
    (12) 205 
Dividing (11) by (12) and taking into account (7), it could be written 206 
( , ( )) 1 ( , ( ))
.( ,0) 1 ( ,0)
in
in
P x c t G F x c t
P x G F x
D
D
       (13) 207 
Substituting ( , ( ))F x c t  from (10) into (13) and using (7), one can obtain 208 
( , ( )) 1 ( ,0) (1 ( , ( )))
.( ,0) 1 ( ,0)
in
in
P x c t G H x FR x c t
P x G H x
       (14) 209 
The left part of (14) is measured in the experiment. ( , ( ))FR x c t  is calculated using the Hill 210 
function (8) with ( , )c x t in this equation being calculated using the diffusion/clearing equation 211 
(1). 212 
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An analytical form of empirical dependence ( ,0)H x , i.e. feedback gain before salicylate 213 
application for different frequencies/locations, can be obtained as follows. Feedback from the 214 
OHCs can be completely blocked in experiments using a high concentration of salicylate. In 215 
this case ( , ( )) 0H x c t   in (12) and the transfer function of the feedback system (Figure 1B) 216 
is equal to the open loop gain .G  Then similar to (11) and (12)  217 
( )
,( )
out
inBlock
P x G
P x
   (15) 218 
where ( )inBlockP x  is the sound pressure required to produce a response from the auditory nerve 219 
in preparations where the cochlear amplifier is completely blocked, and it does not depend on 220 
time. Dividing (11) by (15) and rearranging gives the following equation 221 
( ,0)1( ,0) 1 ,( )
in
inBlock
P xH x
G P x
§ ·  ¨ ¸© ¹
 (16) 222 
where ( ) / ( ,0)inBlock inP x P x  is measured in separate experiments. 223 
G  has frequently been assumed to be constant along the cochlea (e.g. Mountain et al., 1983; 224 
Yates, 1990; Lukashkin and Russell, 1999). In spite of the special design of the cochlea, which 225 
minimised energy losses when the BM travelling wave moves from the base to apex (Jones et 226 
al., 2013), some energy dissipation is still expected during wave propagation in a viscous 227 
environment. To account for energy losses, we assumed a simple linear dependence of the open 228 
loop gain ( ( ))G f x  on frequency 229 
( ( )) ( ) ,G f x s f x i     (17) 230 
where s  is the slope and i  is the intercept defined as 1 ,li s f    with 49.9165lf   kHz 231 
specifying the upper frequency limit of linear dependence for ( ( )).G f x  Hence, ( ( ))G f x  232 
effectively depends only on a single parameter ,s  which could be found by fitting the 233 
experimental data. 234 
Initial model parameters 235 
Ratio ( ) / ( ,0)inBlock inP x P x  was measured as a function of frequency f . Equation (6) shows how 236 
this frequency can be converted to a coordinate. An arbitrary Hill type function 237 
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2
2 21 4
3
( )
m
inBlock
m m
in
P ff m m
P m f
   (18) 238 
was fitted to the experimental data with 1020log  transformation for dB using the Genetic 239 
Algorithm (GA) tool in MATLAB (The MathWorks. Inc. 2018a) (initial local fit). The obtained 240 
1m , 2m , 3m  and 4m  (Table 1) were then used for the later optimisation procedures described 241 
below (final global fit). The feedback gain before application of salicylate 242 
( ,0) ( ( ),0)H x H f x 
 was obtained according to (16) and (18) as  243 
2
2 21 4
3
1( ,0) 1 1/ .
m
m m
fH f m m
G m f
§ ·§ ·   ¨ ¸¨ ¸¨ ¸© ¹© ¹
 (19) 244 
Initial values for the all parameters used in the model before the optimisation procedure are 245 
shown in TABLE 1.  246 
TABLE 1. Model parameter values  247 
Parameter Unit Initial value Optimized value Source of the initial value 
a   mm 0.56 fixed Thorne et al., 1999 
b   mm 0.18 fixed Thorne et al., 1999 
l   mm 18-19 19 Thorne et al., 1999 
dk   mm
2/s 0. 959e-3 fixed Lide, 2002 
/d cratio k k   mm 1-10 1.6968 initial guess 
rwc   mM 100 fixed experiment 
A
  
kHz 0.35 fixed Greenwood, 1990 
D   1/mm 2.1/18.5 fixed Greenwood, 1990 
E
  
- 0.85 fixed Greenwood, 1990 
k
  
mM 0.101 fixed Hallworth, 1997 
n   - 0.983 fixed Hallworth, 1997 
maxV   - 0.71629 fixed Hallworth, 1997 
1m   - 1011.2 fixed experiment 
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2m  - 8.1406 fixed experiment 
3m  kHz 3.4816 fixed experiment 
4m  - 31.686 fixed experiment 
s   1/kHz 0 - 0.0261 0.00014742 initial guess 
 248 
Optimized model parameters 249 
Equation (14) with 1020log  transformation for dB was solved in MATLAB (The MathWorks. 250 
Inc. 2018a) using pdepe solver for partial differential equations and fitted to the entire set of 251 
experimental data for all frequencies and salicylate concentrations using Genetic Algorithm 252 
(GA) tool in MATLAB (The MathWorks. Inc. 2018a). The squared error  253 
2
1
( )
n
i i
i
SE M E
 
 ¦   254 
was used as a cost function for minimisation, where M  are the model predictions and E  are 255 
the experimental data for points 1...i n . It is worth noting that only three model parameters 256 
were fitted during the global fit/optimisation. These parameters are the cochlear length ,l  257 
/d ck k ratio and slope s of the open loop gain ( ( )).G f x   258 
RESULTS 259 
Cochlear amplifier gain  260 
Gain of the cochlear amplifier and corresponding feedback gain of the model, 261 
( ,0) ( ( ),0)H x H f x 
 (equation (16)) was determined empirically from elevation of the CAP 262 
thresholds after application of 1M salicylate solution to the RW which caused a consistent and 263 
steady increase in threshold over the entire frequency range (Figure 2, black circles). Values 264 
for 1m , 2m , 3m  and 4m  (TABLE 1) were determined through fit of the experimental data points 265 
by equation (18) (Figure 2, red curve) using the Genetic Algorithm (GA) tool in MATLAB 266 
(The MathWorks. Inc. 2018a). These values were used for the general optimisation procedure 267 
performed at later stages.  268 
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 269 
Distribution of salicylate along the guinea pig cochlea 270 
100mM solution of salicylate applied to the RW caused a rapid increase followed by saturation 271 
of CAP thresholds for high frequency tones (Figure 3A). CAP threshold increase for tones of 272 
lower frequencies was observed after an initial delay and did not reach saturation during the 273 
time of observation. Any changes in CAP threshold due to application of salicylate were below 274 
the noise floor of measurements for tone frequencies lower than 5 kHz, which corresponds to 275 
approximately the apical 55% of cochlear length (Greenwood, 1990; equation (6)). A partial 276 
recovery of the CAP threshold was observed after salicylate solution was washed out from the 277 
RW confirming that threshold elevation during application of salicylate was due to specific 278 
action of salicylate and not because of general deterioration of preparations. 279 
Pooled data from 5 animals were used to find an optimized set of the model parameters via 280 
fitting the entire set of experimental data using the Genetic Algorithm (GA) tool in MATLAB 281 
(The MathWorks. Inc. 2018a) (see MATERIALS AND METHODS). The combined best fit to 282 
the entire set of experimental data for the optimized set of parameters is illustrated in Figure 283 
3B. Figure S1 shows the same plots for each of the frequencies along the corresponding 284 
 
FIGURE 2. Elevation of CAP thresholds after complete block of the cochlear amplifier 
(left Y-axis) and corresponding value of the open loop and feedback gain (right Y-axis). 
Black circles show the experimental values of threshold elevation. Red curve indicates fit 
of the experimental data points by equation (18). Related values of the parameters 1m , 2m
, 3m  and 4m  are given in TABLE 1. Value of the open loop (magenta curve) and feedback 
(blue curve) gains after the final global optimization procedure were calculated using 
equations (17) and (19), respectively, with the optimized value of parameter s (TABLE 
1). 
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experimental data. It is worth noting, that the optimisation procedure was performed over the 285 
entire experimental set in order to fit the data for all the experimental frequencies 286 
simultaneously (Figure S1). The optimized set of model parameters (TABLE1) found due to 287 
the general optimization procedure was used to predict cochlear responses and concentrations 288 
of salicylate (Figure 3C) along the entire cochlear length and over arbitrary time duration.  289 
The absence of CAP threshold changes at frequencies below 5 kHz was due to poor diffusion 290 
of salicylate from the RW into the cochlear apex. It required increasingly longer times for the 291 
salicylate concentration to reach steady-state in the more apical regions of the cochlea, but at 292 
90% of cochlear length (10 % from the apex), salicylate concentration was about 12 orders of 293 
magnitude smaller than at the base even at steady-state (Figure 3C). The model suggests that 294 
this steep concentration gradient is due mainly to the fast clearing of salicylate from the ST 295 
which is reflected in the small /d ck k  ratio found in the optimization (TABLE 1). Because the 296 
flux J  is proportional to the concentration gradient (equation (A20)), changes in salicylate 297 
concentration at the RW will not lead to changes in the concentration gradient between the 298 
cochlear base and apex. In this case all steady-state curves for different concentrations of 299 
salicylate at the RW are scaled versions of each other (data not shown). Hence, for a specific 300 
substance (i.e. for specific diffusion ( dk ) and clearing ( ck ) coefficients) and for a given 301 
cochlear geometry, the ratio of steady-state concentrations at the base and apex of the cochlea 302 
is a constant and does not depend on substance concentration at the RW. This was further 303 
assessed for the human cochlea. 304 
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 305 
 306 
 
FIGURE 3. CAP threshold elevation (A, B) and salicylate distribution (C) in the guinea 
pig cochlea after application of 100 mM of salicylate solution to the RW at time = 0. (A) 
Representative example of the CAP threshold elevation in a single preparation. Salicylate 
was washed out after 80 minutes of application. (B) Combined best fit of the entire set of 
experimental data on CAP threshold elevation for five preparations (Figure S1) using the 
parameter optimization procedure. Labels indicate percentage of the total cochlear length 
from the base. (C) Salicylate concentration along the cochlear length calculated using the 
optimized values of the model parameters (TABLE 1).  
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Diffusion of an arbitrary substance in the human cochlea 307 
 308 
 
FIGURE 4. Theoretical distribution of an arbitrary substance in the human cochlea. (A) 
Dependence of the ratio of basal ( 10%c ) and apical ( 90%c ) steady-state concentrations on 
the ratio of diffusion ( dk ) and clearing ( ck ) coefficients. Red cross indicates the point for 
salicylate ( / 1.7d ck k  ). (B) Normalized time (black curve, left ordinate) required to reach 
steady-state concentration at the cochlear apex for substances with different ratio of the 
diffusion ( dk ) and clearing ( ck ) coefficients. Red curve shows a specific example of the 
absolute time (right ordinate) for a substance with the diffusion coefficient ( dk ) similar to 
that of dexamethasone. The steady-state was defined as the normalized difference 
between consecutive numerical values of concentration less than 10-4. Jitter in the curves 
for small /d ck k ratios is due to very low apical concentrations. The following geometrical 
parameters for human cochlea were used for calculations using the non-dimensional form 
of the diffusion equation (A33)) 0.7981a   mm, 0.3990b   mm and 28.46l   mm 
(Thorne et al., 1999). 
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Hence, the validity of the diffusion/clearing equation has been confirmed using the 309 
experimental data on salicylate block of the cochlear amplifier, the equation can be used to 310 
make conclusions about the distribution of arbitrary substances along the human cochlea 311 
(Figure 4). Decrease in the relative contribution of clearing into the distribution of a substance 312 
along the ST, i.e. increase of /d ck k ratio, leads to a dramatic reduction in the steady-state, base-313 
to-apex gradient of the substance concentration (Figure 4A) calculated using the non-314 
dimensional form of the diffusion equation (A33). This result is expected because a larger 315 
amount of the substance is available for diffusion into the cochlear apex in this case. For 316 
salicylate, however, the difference between the basal and apical concentrations is even larger 317 
in the human cochlea (red cross in Figure 4A) compared to guinea pigs and reaches 16 orders 318 
of magnitude because of the increased length of the human cochlea.  319 
Figure 4A provides theoretical estimates of the minimal gradients which can be reached along 320 
the ST due to passive diffusion, when substances are in contact with the RW long enough to 321 
establish a concentration equilibrium distribution. Reduction in the base-to-apex gradient for 322 
substances with higher /d ck k ratios, which are better retained in the ST, comes at the expense 323 
of the much longer substance exposure times required to reach steady-state concentration 324 
gradients (Figure 4B). For example, for a drug with the diffusion coefficient dk  similar to 325 
dexamethasone, for which the clearing coefficient is unknown, it takes days of retention at the 326 
RW when realistic /d ck k  ratios are assumed (red curve in Figure 4B). The problem is that, 327 
while it is theoretically possible to achieve smaller base-to apex concentration gradients for a 328 
drug with high /d ck k  ratios, in practice, if the drug is active, it will be cleared from the ST into 329 
the cochlear tissue, hence ck  cannot be arbitrarily small. In this case, the minimal theoretical 330 
difference in the base-to-apex concentrations of the drug is still a few orders of magnitude. 331 
DISCUSSION 332 
The existence of a base-to-apex drug concentration gradient, when drugs are applied to the 333 
RW, has been well established. From this point of view, this study quantifies these gradients 334 
for the intact cochlea when the flow of perilymph in the ST is very small (Ohyama et al., 1988). 335 
This study does not investigate the problem of the RW permeability which is a separate 336 
challenge and requires specific considerations for particular drugs and formulations (Salt and 337 
Plontke, 2018). Instead, sodium salicylate which easily passes through the RW was used to 338 
ensure high concentrations at the cochlear base. Though, passive proton-mediated diffusion of 339 
salicylate across biomembranes is observed at micromolar concentrations (Takagi et al., 1998), 340 
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the RW diffusional barrier could, presumably, be overcome by the drug at the much higher, 341 
submolar concentrations used in this study. While the RW membrane is highly permeable to 342 
salicylate and the CAP threshold elevation at high frequencies started within seconds after 343 
salicylate application, the model assumption that salicylate concentrations on both RW sides 344 
were the same might introduce some error in the calculated absolute concentrations. We would 345 
like to emphasise, however, that an error in calculation of the absolute concentrations (note that 346 
the absolute concentrations were calculated using Hallworth¶V (1997) empirical dependence 347 
between salicylate concentration and the OHC force reduction) does not lead to an error in 348 
calculation of the concentration gradient which is the basis for the conclusions in this study. 349 
This is true because the flux J  is proportional to the concentration gradient (equation (A20)) 350 
and gradient curves calculated for different salicylate concentrations at the RW are scaled 351 
versions of each other with the same gradients.  It is worth noting that, from discoveries we 352 
made in our preliminary experiments, salicylate concentrations higher than 100 mM used to 353 
study diffusion in this work caused elevation of CAP thresholds throughout the entire 354 
frequency range. This flooding of the whole cochlea with salicylate was due apparently to 355 
overloading of the cochlear clearing and other possible mechanisms involved. In this case, the 356 
dynamic equilibrium between diffusion and clearing and steady-state salicylate concentrations 357 
cannot be reached and our model cannot be applied. From an experimental standpoint, the use 358 
of higher concentrations of salicylate also made time-dependent estimates of diffusion 359 
impossible for high frequencies because the clearing mechanism in the basal turn became 360 
almost immediately saturated following salicylate application. As a result of the clearing 361 
overload and other unidentified processes, salicylate is accumulated throughout the cochlea 362 
affecting all the frequencies as it was observed in our experiments where we applied 1M 363 
salicylate to the RW. Of course, therapeutic use of concentrated drug formulations in order to 364 
overcome the issues raised by this study could be problematic due to likely side effects and/or 365 
restricted aqueous solubility and thus is not a practical solution. 366 
While the steady-state distribution of concentrations, which is the basis for conclusions in this 367 
study, is fitted well by the simple diffusion model, the responses for the lower frequencies 368 
became gradually slower compared to the model predictions (Figure S1). This may happen 369 
because salicylate action on the cochlear amplifier is not limited by its block of the OHC 370 
motility (e.g. Russell and Schauz, 1995; Wu et al., 2010) as it is assumed in the model. A 371 
compensatory effect from a hypothetical mechanism maintaining cochlear homeostasis and 372 
2+&VHQVLWLYLW\DQGUHVSRQVLEOHIRUWKHµERXQFH¶SKHQRPHQRQDIWHUH[SRVXUHWRORXGVRXQGV373 
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(Kirk et al., 1997; Drexl et al., 2014) may also explain delayed threshold elevation at subtle 374 
salicylate concentrations in the low-frequency cochlear region. Finally, salicylate 375 
concentration at the cochlear base may be diluted by the cerebrospinal fluid coming through 376 
the cochlear aqueduct into the perilymph which becomes hyperosmotic due to relatively high 377 
salicylate concentration at the base. None of these mechanisms should, however, affect our 378 
conclusion about the magnitude of the steady-state concentration gradients along the ST. 379 
For a cochlea of given geometry, the concentration gradient along the ST depends only on the 380 
relationship between diffusion and clearing and is drug specific. In terms of the current study, 381 
it is the value of ,/d ck k  which defines the ratio between the amount of drug entering through a 382 
unit surface of the ST normal to the direction of diffusion and leaving it through a unit area of 383 
the side walls within the same time period. Salicylate, which is readily cleared from the ST (384 
1 9/ .6 68d ck k  ), does not in practice diffuse into the cochlear apex and the resultant theoretical 385 
base-to-apex concentration gradient is extremely high (red cross in Figure 4A). Drugs which 386 
are better retained in the ST (i.e. have higher /d ck k ratio) form smaller concentration gradients, 387 
but this is traded for the considerably longer time it takes for these drugs to reach steady-state 388 
concentrations in the cochlear apex (Figure 4B). Hence, this approach may not be practical 389 
when there is only a short time window for the treatment of a specific cochlear disorder. Also, 390 
using a drug form which is better retained in the ST will lead to larger concentration differences 391 
between the ST and surrounding tissue. This may be a problem for drugs with narrow 392 
therapeutic windows unless an inactive form of the drug is used for even distribution along the 393 
ST through diffusion and it is activated only when the drug is cleared into the surrounding 394 
tissue. 395 
Because the retention of a drug at the RW does not lead to a levelling of its concentration along 396 
the cochlear spiral (see also Plontke et al., 2007b), different strategies for drug delivery to the 397 
cochlear apex should be employed. Stable drug loaded nanocarriers (Zou et al., 2014; Li et al., 398 
2017; Kamalov et al., 2018) which can stay in the ST long enough without being cleared into 399 
the surrounding tissue may be a feasible option. When the concentration of nanocarriers along 400 
the ST reaches a constant level, the encapsulated drug could be released from the carriers 401 
through thermal or light activation (Karimi et al., 2016; Yuan et al., 2017; Karimi et al., 2017) 402 
to obtain sufficient drug concentrations along the entire cochlear spiral. A potential problem 403 
with this approach is the substantial increase in time required to reach the equilibrium base-to-404 
apex gradient of nanocarrier concentrations, due to the substantially smaller diffusion 405 
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coefficients of even the smallest liposomes and micelles, compared to lone drug molecules 406 
(Figure 4B) (del Amo et al., 2017). 407 
Drug loaded nanoparticles, however, could be used to take advantage of anatomical and cellular 408 
feature of the cochlea which enable drug uptake through routes and pathways other than the 409 
ST route (Glueckert et al., 2018). Disulfiram loaded nanoparticles, for example, were observed 410 
in the apical part of the spiral ganglion just one day after their application to the RW and 411 
elevation of auditory brainstem response thresholds, due to disulfiram induced apoptosis of the 412 
ganglion neurons, was detected for frequencies corresponding to the cochlear apex within two 413 
days after application (Buckiová et al., 2012). Nanoparticles can also be effectively driven and 414 
distributed along the entire cochlea. Assisted diffusion of magnetically driven, prednisolone-415 
loaded magnetic nanoparticle along the cochlea resulted in a significant increase in the 416 
protective effect of the drug against cisplatin-induced ototoxicity compared to intratympanic 417 
injections of prednisolone (Ramaswamy et al., 2017).  418 
This study investigates passive drug diffusion along the intact cochlea when the drug is applied 419 
to the RW and highlights intrinsic problems with this method of local drug administration into 420 
the inner ear. Retaining drugs at the RW for an arbitrarily long time does not decrease its base-421 
to-apex concentration gradient, which, at steady state, depends solely upon the relationship 422 
between drug diffusion along and clearing from the ST. Usage of drug-loaded nanocarriers 423 
which utilize the anatomical and cellular properties of the cochlea, and which can be actively 424 
distributed along the entire length of the cochlea seems to be a more promising approach. 425 
APPENDIX  426 
Only diffusion along the long axis x of the tube of decreasing diameter is considered (Figure 427 
1A). The concentration c  within each cross-section for a fixed instance t is assumed to be 428 
constant, i.e. ( , )c c x t  is independent to the y axis. If the area of the cross-section is ( )S x , 429 
then the flux J  along the x axis is given by: 430 
( , )( , ) ( ) ,d
dc x tJ x t S x k
dx
     (A20) 431 
where dk  is the diffusion coefficient. 432 
At the same time the clearing of salicylate from the tube of length x' , its perimeter ( )P x  and 433 
with an area of surface ( )P x x' , can be described as: 434 
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( , ) ( , ) ( ) ,cCl x t c x t k P x x   '  (A21) 435 
where 
ck  is the clearing coefficient. 436 
The balance of fluxes and clearing in the volume between 0x  and 1x  can be described as: 437 
01
1 0
( , )( , )( , )( ) ( ) ( ) ( , ) ( ) ,d d c
dc x tdc x tdc x tS x x S x k S x k c x t k P x x
dt dx dx
'           '  (A22) 438 
where 1 0x x x'    is positive and x  is in 0 1[ , ]x x . 439 
Divide both sides of Eq (A22) by x'  and rearrange it as follows: 440 
1 1 0 0( ) ( , ) / ( ) ( , ) /( , )( ) ( , ) ( ).d d c
S x k dc x t dx S x k dc x t dxdc x tS x c x t k P x
dt x
        '  (A23) 441 
Take the limit of x'  converging to zero and divide by ( )S x , the following is obtained: 442 
( , ) 1 ( , )( ) ( , ) ( ),( ) d
dc x t d dc x tS x k c x t L x
dt S x dx dx
§ ·     ¨ ¸© ¹  (A24) 443 
where ( )( ) ( )c
P xL x k
S x
 
 is an integral coefficient of clearing. 444 
The perimeter is 445 
( ) 2 ( )P x mx aS    (A25) 446 
and the area is 447 
 2( )S x mx aS   , (A26) 448 
where ( ) /m b a l  .  449 
The integral coefficient can be written as: 450 
2( )( ) .( ) ( )
c
c
kP xL x k
S x r x
    (A27) 451 
Thus, the diffusion can be described by the following partial differential equation  452 
2( , ) 1 ( , )( ) ( , ) ,( ) ( )
c
d
kdc x t d dc x tS x k c x t
dt S x dx dx r x
§ ·     ¨ ¸© ¹  (A28) 453 
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with the boundary conditions 454 
(0, ) ,rwc t c   (A29) 455 
( , ) 0d
dc l tk
dx
   (A30) 456 
and initial conditions 457 
(0,0) ; 0,rwc c x   (A31) 458 
( ,0) 0; 0.c x x !   (A32) 459 
Equation (A28) can be rewritten in the following non-dimensional form 460 
   
2
2
2
( , ) 1 ( , ) 2 /( ) ( , ) ,( )( )
du d du l ratiob a a u
d d d b a ab a a
F W F WF F WW F F FF
§ ·      ¨ ¸    © ¹  (A33) 461 
with the boundary conditions 462 
(0, ) 1,u W    (A34) 463 
(1, ) 0duratio
d
W
F   (A35) 464 
and the initial conditions 465 
(0,0) 1; 0,c F    (A36) 466 
( ,0) 0; 0,c F F !  (A37) 467 
where / rwu c c , 2/dt k lW    and /x lF  . 468 
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